Seasoned investor and operator with experience across technology and healthcare, Michael Fogel brings cross‑border deal experience, portfolio company governance and growth-stage capital deployment expertise to institutional investors. He has led angel and venture investments, sat on operating boards, and advised strategic M&A and capital-raising processes. His profile suits LPs seeking hands-on co-investment partners and growth equity exposure.
Seasoned investor and operator with experience across technology and healthcare, Michael Fogel brings cross‑border deal experience, portfolio company governance and growth-stage capital deployment expertise to institutional investors. He has led angel and venture investments, sat on operating boards, and advised strategic M&A and capital-raising processes. His profile suits LPs seeking hands-on co-investment partners and growth equity exposure.
Brings a growth-oriented, hands-on investment approach focused on technology and healthcare companies at the growth stage, with a bias toward cross-border opportunities and scalable business models. Prefers concentrated, active stakes where governance influence and operational involvement accelerate revenue scaling, product expansion, and exit readiness. Capital allocation favors follow-on-ready portfolio companies with clear paths to strategic M&A or institutional rounds; underwriting blends fundamental unit-economics analysis with founder quality and go-to-market defensibility. Time horizon is multi-year growth equity to late‑stage venture, with disciplined risk management via board-level oversight, staged capital deployment, and selective co-investment with institutional LPs and strategic partners.
Brings a growth-oriented, hands-on investment approach focused on technology and healthcare companies at the growth stage, with a bias toward cross-border opportunities and scalable business models. Prefers concentrated, active stakes where governance influence and operational involvement accelerate revenue scaling, product expansion, and exit readiness. Capital allocation favors follow-on-ready portfolio companies with clear paths to strategic M&A or institutional rounds; underwriting blends fundamental unit-economics analysis with founder quality and go-to-market defensibility. Time horizon is multi-year growth equity to late‑stage venture, with disciplined risk management via board-level oversight, staged capital deployment, and selective co-investment with institutional LPs and strategic partners.
| Trades 67 | Longs Won 34/67 50% | Profit Factor 0.47 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $2.7M |
| Average Win $319,873.6 | Best Trade (Jun 29) $2.24M | Sharpe Ratio -12.07 |
| Average Loss -$694,864.61 | Worst Trade (Mar 30) -$21.67M | Z-Score -0.98 (67.47%) |
| Commissions $0 | Avg. Trade Length 4m 1w | Expectancy -$74,709.22 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | - | - | - | - | - | - | - | - | - | - |
| Consecutive Losing Trades | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|